Drug Discovery & DDS– category –
-
Drug Discovery & DDS
Eli Lilly’s Retatrutide Achieves Unprecedented Weight Loss in Pivotal Phase 3 Obesity Trial
Eli Lilly and Company (PRNewswire), Healthline, BioPharma Dive, The Guardian, BioSpace, GlobalData USA Overview Eli Lilly's triple hormone receptor agonist, retatrutide (GIP, GLP-1, and glucagon), demonstrated powerful and clinically mea... -
Drug Discovery & DDS
Key FDA Approvals Anticipated for GLP-1 Pipeline in May 2026 Update
Prime Therapeutics - Portal USA Overview Four significant FDA approval decisions for GLP-1 related medications are expected in 2026, marking critical advancements in metabolic disease management. Eli Lilly's injectable Mounjaro is antici... -
Drug Discovery & DDS
Eli Lilly Seals Landmark $2.75 Billion AI Drug Discovery Alliance with Insilico Medicine
IntuitionLabs, TipRanks, Tech Funding News USA Overview Pharmaceutical giant Eli Lilly has forged a strategic drug discovery and development collaboration with AI biotech pioneer Insilico Medicine, valued at up to $2.75 billion. The deal... -
Drug Discovery & DDS
European Biotechs Drive Next-Gen Cell & Gene Therapy Manufacturing Innovation
BioSpace UK Overview European biotechnology firms are making significant strides in cell and gene therapy (CGT) manufacturing, focusing on scalability and automation. UK-based Oxford Biomedica, a leading viral vector CDMO, specializes in... -
Drug Discovery & DDS
Drug Discovery & DDS Weekly Report May 24, 2026
🎙 Podcast May 24, 2026 (MP3) — Play & Download DrugDiscovery_DDSEnglishPodcast_20260524.mp3Download -
Drug Discovery & DDS
Henlius Gains NMPA IND Approval for HLX48, a Bispecific c-Met/EGFR Antibody-Drug Conjugate for Solid Tumors
FirstWord Pharma China Overview Shanghai Henlius Biotech, Inc. announced that its self-developed c-Met/EGFR bispecific antibody-drug conjugate (ADC), HLX48, has received Investigational New Drug (IND) approval from China's National Medic... -
Drug Discovery & DDS
Beyond GLP-1: Next-Gen Obesity Drug Race Accelerates with Multi-Agonist Therapies
The Elec Inc. South Korea Overview The race for next-generation obesity drugs is expanding beyond GLP-1 injections into multi-agonist therapies targeting multiple hormones. Eli Lilly's Retatrutide, a triple agonist for GLP-1, GIP, and gl... -
Drug Discovery & DDS
NEOK002: Next-Generation Bispecific ADC Targeting EGFR and MUC1 Enters Clinical Development for Solid Tumors
Conference Coverage AACR USA Overview NEOK002 (formerly ABL209), a bispecific antibody-drug conjugate (ADC), has entered clinical development, designed to concurrently target two key cancer antigens, EGFR and MUC1, implicated in epitheli... -
Drug Discovery & DDS
BeOne Medicines’ BEQALZI™ (Sonrotoclax) Gains US FDA Approval for Relapsed/Refractory Mantle Cell Lymphoma as First BCL2 Inhibitor
Stock Titan USA Overview BeOne Medicines announced that BEQALZI™ (sonrotoclax) has received U.S. FDA approval for the treatment of relapsed/refractory Mantle Cell Lymphoma (MCL), marking it as the first BCL2 inhibitor for this indication... -
Drug Discovery & DDS
GSK’s Bepirovirsen for Chronic Hepatitis B Receives FDA Priority Review and Breakthrough Therapy Designation
GSK USA Overview GSK announced that its investigational antisense oligonucleotide (ASO), Bepirovirsen, a candidate for chronic Hepatitis B, has been granted both Priority Review and Breakthrough Therapy Designation (BTD) by the U.S. FDA....